Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 5/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.45 |
| ▸ | CCR8 | P51685 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625158 | 0.83 | HCAR2 (0.44) | MAPTCYP1A2CYP2D6CYP19A1CYP2C9 | |
| SCHEMBL2237883 | 0.82 | ADRB2 (0.51) | CYP3A4MAPTCYP1A2CYP2D6CYP19A1 | |
| SCHEMBL16781356 | 0.82 | CXCR4 (0.50) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL505581 | 0.79 | ADRB2 (0.62) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL30083578 | 0.79 | ADRB2 (0.62) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL12327091 | 0.79 | CCNE1 (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18179877 | 0.79 | MAOA (0.52) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL13315147 | 0.79 | CYP2D6 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL14957567 | 0.79 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5991973 | 0.78 | ADH1B (0.55) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS | 2017-02-02 | — | — | US | disclosed |
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| CN-103483242-A | Preparation methods of 4-(2'-pyridyl)benzyl hydrazine and its intermediate | SHANGHAI PUYI CHEMICAL CO LTD | 2014-01-01 | — | — | CN | disclosed |
| WO-2012170792-A1 | ATAZANAVIR METABOLITE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| WO-2010144869-A2 | PROTEASE INHIBITORS | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010103473-A1 | METHOD OF TREATMENT OF POLYCYSTIC DISEASES AND CHRONIC LYMPHOCYTIC LEUKEMIA | CHU DE BREST (FR) | 2010-09-16 | — | — | WO | disclosed |
| EP-2094661-A2 | PROCESS FOR THE PREPARATION OF ATAZANAVIR | FIDIA FARMACEUTICI S.p.A. (IT) | 2009-09-02 | — | — | EP | disclosed |
| EP-1930324-A1 | Process for the preparation of atazanavir | SOLMAG S.p.A. (IT) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008065490-A2 | PROCESS FOR THE PREPARATION OF ATAZANAVIR | FIDIA FARMACEUTICI S.P.A. (IT) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | IDO1 1007/4885CYP3A4 211/4885MAPT 814/4885 |
| US-20170028077-A1 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | SERPINB1, SPINT2, TMPRSS15 | IDO1 561/4885CYP3A4 5/4885MAPT 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.